Pipeline
Ryvu Therapeutics is advancing a broad pipeline by addressing emerging targets in oncology.
Our pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinase, synthetic lethality, immuno-oncology and immunometabolism pathways.
Clinical Projects
- Program/ Target Name
- Indication
- Discovery
- Preclinical
- Phase I
- Phase II
- Partner
- Anticipated
Milestones
- SEL24 (MEN1703)
PIM/FLT3
- RVU120
CDK8/19 -
- AML/MDS
-
-
-
-
-
- SOLID TUMORS
-
-
-
-
-
Initiation of Phase I
2021
Discovery & Preclinical Projects
- Program/ Target Name
- Indication
- Discovery
- Preclinical
- Phase I
- Phase II
- Partner
- Anticipated
Milestones
Synthetic Lethality
- PRMT5
-
- Solid tumors
-
-
-
-
-
- WRN
-
- Solid tumors
-
-
-
-
-
- NOVEL TARGETS
-
- ONCOLOGY
-
-
-
-
-
Immuno-oncology
- HPK1
-
- Solid tumors
-
-
-
-
-
Pre-clinical candidate
2022
- STING
-
- Solid tumors
-
-
-
-
-
IND filing
2022
- Discovery Collaborations
-
-
